Present treatment for chronic obstructive pulmonary disease (COPD) has a certain role in reducing COPD exacerbation and hospitalization, improving the life quality, and postponing the lung function decline. But for some patients with severe COPD, current treatment only partially alleviates the symptoms and has little role in the lung function decline. In this randomized, multicenter study, the investigators evaluate the safety and efficacy of bosentan in the treatment of grade Ⅲ or Ⅳ COPD patients with pulmonary hypertension detected by echocardiography. The primary endpoint is the frequency of COPD exacerbation, and the secondary endpoint includes changes of lung function, 6-min-walk distance (6-MWD), SGRQ score and mMRC/CAT score.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
The second affiliated hospital of xi'an jiaotong university
Xi'an, Shaanxi, China
RECRUITINGThe department of pulmonary and critical care medicine, Xijing hospital
Xi'an, Shaanxi, China
RECRUITINGThe department of pulmonary and critical care medicine, Tangdou hospital
Xi'an, Shaanxi, China
RECRUITINGThe first affiliated hospital of xi'an jiaotong university
Xi'an, Shaanxi, China
RECRUITINGShaanxi Provincial People'S Hospital
Xi'an, Shaanxi, China
RECRUITINGFrequency of COPD Exacerbation
Time frame: 12 months
6-min-walk distance (6-MWD)
Time frame: 12 months
Lung Function
Time frame: 12 months
mMRC/CAT score
Time frame: 12 months
SGRQ score
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.